Protemix Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 4

Protemix General Information

Description

Manufacturer of novel bio-pharmaceutical drugs for the treatment of cardiovascular disease, diabetes and other metabolic disorders. The company also develops compounds for the treatment of diabetic and non-diabetic heart failures.

Contact Information

Website
www.protemix.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Level 28 IAG House, 151 Queen Street
  • PO Box 2165
  • Auckland
  • New Zealand
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Vertical(s)
Manufacturing, Life Sciences
Corporate Office
  • Level 28 IAG House, 151 Queen Street
  • PO Box 2165
  • Auckland
  • New Zealand

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Protemix Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Protemix‘s full profile, request access.

Request a free trial

Protemix Patents

  • 47

    Total Documents Applications and Grants

  • Total Patents Families

  • 4

    Granted

  • Pending

  • Expiring in next 12 mo

Protemix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-1948160-A4 Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits Inactive 09-Nov-2005
EP-1948160-A1 Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits Inactive 09-Nov-2005
EP-1877801-A1 Copper regulation evaluation and therapy Inactive 25-Apr-2005
EP-1877801-A4 Copper regulation evaluation and therapy Inactive 25-Apr-2005
CA-2590177-A1 Glyponectin (glycosylated adiponectin) for the treatment of diseases and conditions Inactive 10-Dec-2004 A61K38/17
To view Protemix’s complete patent history, request access »

Protemix Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Protemix‘s full profile, request access.

Request a free trial

Protemix FAQs

  • When was Protemix founded?

    Protemix was founded in 1998.

  • Where is Protemix headquartered?

    Protemix is headquartered in Auckland, New Zealand.

  • What industry is Protemix in?

    Protemix’s primary industry is Biotechnology.

  • Is Protemix a private or public company?

    Protemix is a Private company.

  • What is Protemix’s current revenue?

    The current revenue for Protemix is .

  • How much funding has Protemix raised over time?

    Protemix has raised $26.1M.

  • Who are Protemix’s investors?

    Birnie Capital Partners, NovaQuest Capital Management, Novartis Venture Fund, and Pharmaceutical Innovations have invested in Protemix.

  • When was Protemix acquired?

    Protemix was acquired on 11-Oct-2010.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »